News | FDA

Top News

HHS OIG Issues Special Fraud Alert on Speaker Programs

Full Article

November 17, 2020
NHLBI Trial Changes Protocol and Informed Consent After Public Citizen Complaint to OHRP

Full Article

October 13, 2020
HHS Finalizes Rule Permitting Importation of Rx Drugs from Canada; ‘Significant’ Savings Foreseen

Full Article

October 1, 2020
HHS Blocks FDA From Requiring Premarket Review of Laboratory-Developed Tests Without Rulemaking

Full Article

September 2, 2020
FDA Issues Final Guidance on Civil Money Penalties for ClinicalTrials.gov Reporting Violations

Full Article

August 17, 2020

LATEST HEADLINES

PhRMA Issues Guidance for Enhancing Trial Diversity

November 22, 2020
Draft Guidance Details Electromagnetic Compatibility Data To Provide to FDA in Device Submissions

November 19, 2020
Federal Bankruptcy Court Approves DOJ's $8 Billion Global Settlement with Purdue Pharma

November 18, 2020
HHS OIG Issues Special Fraud Alert on Speaker Programs

November 17, 2020
FDA Issues Final Guidance on Certificates of Confidentiality

November 17, 2020
FDA Posts Draft Guidance on Voluntary Disclosure of Sesame as Allergen

November 12, 2020
Ninth Circuit Refuses To Block Civil Enforcement Action by Hawaii Against Plavix Manufacturers

November 11, 2020
Kentucky Supreme Court Reverses Preemption-Based Ruling Against Plaintiffs Involving Catheter with IDE

November 11, 2020
FDA Issues Final Guidance on Trial Diversity

November 10, 2020
Medtronic Agrees To Pay $9.2 Million To Settle FCA Case

November 8, 2020

Latest FDA Intelligence

Administration’s Most Favored Nation Pricing Plan Could Affect Industry Profitability

November 23, 2020
What Does a Biden Administration Mean for Medical Product Promotion Regulation?

November 10, 2020
Tom Abrams’ Legacy at OPDP

October 7, 2020
New Normal for Ad Promo Is Likely the Old Normal

September 11, 2020
Limitations of Promotional Claims on Facial Masks Marketed under Emergency Use Authorizations

September 9, 2020

NEWSLETTERS

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1606220922
            [c] => 1606220922
            [l] => 2000000
        )

)

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1606220922
            [c] => 1606220922
            [l] => 2000000
        )

    [fda] => Array
        (
            [last_user_access] => 
        )

)

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1606220922
            [c] => 1606220922
            [l] => 2000000
        )

    [fda] => Array
        (
            [last_user_access] => 
        )

)

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1606220922
            [c] => 1606220922
            [l] => 2000000
        )

    [fda] => Array
        (
            [last_user_access] => 
        )

)

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1606220922
            [c] => 1606220922
            [l] => 2000000
        )

    [fda] => Array
        (
            [last_user_access] => 
        )

)

Top News

HHS OIG Issues Special Fraud Alert on Speaker Programs

NHLBI Trial Changes Protocol and Informed Consent After Public Citizen Complaint to OHRP

HHS Finalizes Rule Permitting Importation of Rx Drugs from Canada; ‘Significant’ Savings Foreseen

HHS Blocks FDA From Requiring Premarket Review of Laboratory-Developed Tests Without Rulemaking

FDA Issues Final Guidance on Civil Money Penalties for ClinicalTrials.gov Reporting Violations

LATEST HEADLINES

Latest FDA Intelligence

Administration’s Most Favored Nation Pricing Plan Could Affect Industry Profitability

What Does a Biden Administration Mean for Medical Product Promotion Regulation?

Tom Abrams’ Legacy at OPDP

New Normal for Ad Promo Is Likely the Old Normal

Limitations of Promotional Claims on Facial Masks Marketed under Emergency Use Authorizations

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT